glycoprotein IIb/IIIa inhibitor
Pronunciation: GLY-ko-pro-teen two-B three-A
A class of antiplatelet medications that block the final common pathway of platelet aggregation, used in high-risk percutaneous interventions.
Full Definition
Glycoprotein IIb/IIIa inhibitors are potent intravenous antiplatelet agents that block the glycoprotein IIb/IIIa receptor on platelets, preventing fibrinogen binding and platelet aggregation. These medications represent the most potent antiplatelet therapy available and are reserved for high-risk percutaneous coronary interventions, particularly in patients with large thrombus burden or acute coronary syndromes. Common agents include abciximab, eptifibatide, and tirofiban. The main risk is bleeding, requiring careful monitoring and appropriate dosing adjustments in renal impairment.
Usage
Usage note: Use Roman numerals IIb/IIIa; GP IIb/IIIa is acceptable abbreviation in clinical contexts.
In Context
- "A glycoprotein IIb/IIIa inhibitor was initiated due to high thrombus burden." — Medication management
- "Bleeding time was prolonged following glycoprotein IIb/IIIa inhibitor administration." — Adverse event reporting